^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Braftovi (encorafenib)

    i
    Other names: W-0090, W 0090, LGX818, NVP-LGX818, NVP-LGX818-NXA, ONO-7702, PF-07263896, W0090, LGX-818, LGX 818, NVPLGX818, NVP LGX818, ONO7702, ONO 7702, PF07263896, PF 07263896
    Company:
    Medison, Nerviano Medical Sciences, Ono Pharmaceutical, Pfizer, Pierre Fabre
    Drug class:
    BRAF V600E inhibitor, cRAF inhibitor
    Related drugs:
    Apply
    Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib (SuRage-EB) (NCT07092410)
    Phase 4
    SRH Wald-Klinikum Gera GmbH
    Not yet recruiting
    Last update posted :
    07/29/2025
    Initiation :
    08/01/2025
    Primary completion :
    08/01/2030
    Completion :
    08/01/2030
    BRAF
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    UK ENcorafenib and BInimetinib Real-world Study in Melanoma (UK-EnBiRiM) (NCT07022457)
    Phase N/A
    Vitaccess Ltd
    Not yet recruiting
    Last update posted :
    06/15/2025
    Initiation :
    06/23/2025
    Primary completion :
    12/06/2027
    Completion :
    12/06/2027
    BRAF
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER) (NCT04607421)
    Phase 3
    Pfizer
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/21/2020
    Primary completion :
    01/06/2025
    Completion :
    12/24/2026
    BRAF
    |
    BRAF V600E • BRAF V600
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Braftovi (encorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Zirabev (bevacizumab-bvzr) • Khapzory (levoleucovorin) • levoleucovorin calcium
    Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer (NCT06102902)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/05/2024
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    BRAF
    |
    BRAF V600E
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • ZEN-3694
    Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. (ECLYPse) (NCT06640166)
    Phase 2
    Fondazione Policlinico Universitario Agostino G...
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    06/03/2024
    Primary completion :
    12/31/2025
    Completion :
    06/30/2026
    BRAF
    |
    Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium
    A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) (NCT05039177)
    Phase 1/2
    Erasca, Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/20/2021
    Primary completion :
    08/01/2025
    Completion :
    12/01/2025
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (C4901001) (NCT05538130)
    Phase 1
    Pfizer
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/30/2022
    Primary completion :
    12/31/2027
    Completion :
    07/03/2029
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • claturafenib (PF-07799933) • polfurmetinib (PF-07799544)
    A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings (NCT05954546)
    Phase N/A
    Pfizer
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    07/21/2023
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    BRAF
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    ZN-c3 in Adult Participants With Metastatic Colorectal Cancer (ZN-c3-016) (NCT05743036)
    Phase 1
    K-Group, Beta, Inc., a wholly owned subsidiary ...
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    02/27/2023
    Primary completion :
    07/16/2024
    Completion :
    09/25/2026
    BRAF
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • azenosertib (ZN-c3)
    Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) (NCT03839342)
    Phase 2
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    06/07/2019
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    BRAF • KIAA1549
    |
    BRAF mutation • BRAF V600K • BRAF fusion
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases (NCT05026983)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    12/27/2021
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE) (NCT06194929)
    Phase 1/2
    University of Utah
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    03/07/2024
    Primary completion :
    01/15/2028
    Completion :
    01/15/2030
    NF1 • RAS
    |
    BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation
    |
    Braftovi (encorafenib) • Avmapki (avutometinib) • Fakzynja (defactinib)